Boditech Highlights Automated Benchtop and Handheld Immunoassay Readers at MEDICA 2022
|
By LabMedica International staff writers Posted on 15 Nov 2022 |

Boditech Med (Gang-won-do, Korea) is presenting its portfolio of latest IVD solutions, including TDM, AMS, and TB diagnostic tests, at this year's MEDICA, the world's largest annual medical technology trade fair, which is taking place from 14-17 November in Düsseldorf, Germany.
At MEDICA 2022, Boditech is showcasing the AFIAS-1 immunoassay analyzer with an all-in-one cartridge system. The AFIAS-1 is a compact, single channel lateral flow immunoassay platform with a disposable cartridge that includes all the reagents necessary for the test. Also on display is the Boditech Quick COVID-19 Ag Nasal quick and simplified rapid test kit that determine COVID-19 antigen with a nasopharyngeal or nasal swab. Boditech Quick COVID-19 Ag Nasal can help to quickly and accurately determine the presence or absence of SARS-CoV-2 antigen at anytime and anywhere. It is very useful as a screening test for SARS-CoV-2 virus infection (COVID-19).
Among its other diagnostic tests, Boditech is highlighting the Alpha-Fetoprotein (AFP) test for diagnosing cancers (liver, testicles and ovaries) & monitoring the therapeutic effect. High levels of AFP in adults may indicate the possibility of the liver, the ovaries, or the testicles, as well as noncancerous liver diseases such as cirrhosis and hepatitis. The AFP plus measures the level of AFP to help diagnose or rule out related abnormalities. Visitors to Boditech’s booth at MEDICA 2022 can also get insights into the company’s AFIAS MxA/CRP combo test that assists in diagnosing viral & bacterial infections by measuring virus-specific markers and CRP simultaneously. The AFIAS MxA/CRP combo test is available on the company’s AFIAS-1, AFIAS-3, AFIAS-6, and AFIAS-10 instruments to support the diagnosis of viral and/or bacterial infection. Boditech has also announced that it will be officially launching its new ichroma Cyfra21-1 which is a tumor marker of NSCLC (non-small cell lung cancer) in early December.
Related Links:
Boditech Med
Latest MEDICA 2022 News
- Bosch Demonstrates Vivalytic All-In-One PCR Analyzer at MEDICA 2022
- Biovendor Group Presents CLIA Solution for Complex Diagnostics at MEDICA 2022
- Diatron Exhibits Advanced Hematology and Clinical Chemistry Analyzers at MEDICA 2022
- Immundiagnostik AG Presents New PCR Test MutaPLEX RespiraScreen4_Diff_seqc at MEDICA 2022
- Eurotrol Presents the Future of Blood Gas Controls at MEDICA 2022
- Rhinomed Announces European Launch of Revolutionary New Swab for Testing Children for Respiratory Diseases

- Absology Exhibits POCT Immunoassay Analyzer with Testing Time of Five Minutes
- Cormay Diagnostics Introduces True 5+ DIFF Multi-Patented Hematology Solution at MEDICA 2022
- EDAN Takes its Solutions up a Notch at MEDICA 2022
- Bioneer Presents Near-Patient POC Molecular Diagnostic System at MEDICA 2022
- Rhinostics Features New RHINObot Automated Decapper at MEDICA 2022
- MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022
- Oxford Immunotec Showcases Automated T-SPOT.TB Test at MEDICA 2022
- Co-Diagnostics Introduces its CoPrimer Technology and Applications at MEDICA 2022
- Sentinel Diagnostics Presents New Fully Automated Sample to Result System for Diagnosis of Viral Infections
- Serosep Exhibits EntericBio System for Testing, Detecting and Identifying GI Pathogens at MEDICA 2022
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more
Rapid Point-of-Care RT-PCR Test Differentiates Influenza A/B and SARS-CoV-2 in Minutes
Respiratory viruses such as influenza A/B and SARS‑CoV‑2 continue to burden urgent care and emergency settings, where rapid, reliable differentiation guides therapy and infection control.... Read moreHematology
view channel
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read more
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read moreImmunology
view channel
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more








